Did You Know...
...that the Eveready Battery began as an invention called the "electric flowerpot," which was a tube with a battery and light bulb inside? The idea was to fasten this gizmo to the side of a flowerpot so it would illuminate the flowers from the bottom. The idea died on the vine and the businessman who licensed the flower pot, Conrad Huber, was left with a pile of useless tubes -- until he found a way to market them as batteries to light the world!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8133494 | Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2 The invention relates to polynucleotides encoding modified immunogenic HIV-1 South African subtype C Env polypeptides. The modifications to the Env polypeptides include deletions of V1, V2 and the stem region. The expression cassettes may be used, for example, to ex... | 03/13/2012 |
| 8124102 | Method for the reduction of viral loads in patients comprising the administration of -deficient human immunodeficiency virus (HIV) A therapeutic suspension for the treatment of human immunodeficiency virus type I (HIV-1) infection in humans using isolated and purified HIV-1 nef-deficient viral particles having a nef-deletion between the endonuclease cleavage sites Nco I and Xho I. ... | 02/28/2012 |
| 8119144 | HIV-1 Clade A consensus sequences, antigens, and transgenes The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field isolates wherein the antigen sequences are closely related to the these ... | 02/21/2012 |
| 8071107 | Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates t... | 12/06/2011 |
| 8048431 | Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to... | 11/01/2011 |
| 8003113 | DNA vaccine compositions and methods of use The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered saf... | 08/23/2011 |
| 7981430 | Multi-clade chimeric immunogens derived from highly conserved regions of the human immunodeficiency virus type 1 (HIV-1) consensus proteome The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV protein... | 07/19/2011 |
| 7943146 | Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the f... | 05/17/2011 |
| 7939083 | Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide... | 05/10/2011 |
| 7892562 | Methods of inducing TH-1 immune responses to HIV-1 by administering UV/psoralen-treated desialated inactiviated HIV-1 virions deficient in CD55 and CD59 Administration protocols for a fusion protein, matrix protein and psoralen inactivated HIV based immunogenic composition that induces an immune response to HIV. The immunogenic compositions are based on HIV biologically active fusion peptide, matrix peptide, or psor... | 02/22/2011 |
| 7815916 | Cloning and expression of HTLV-III DNA The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be emplo... | 10/19/2010 |
| 7811580 | Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes Env-CD4 complexes and hybrids are disclosed that expose cryptic epitopes that are important in virus neutralization. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. ... | 10/12/2010 |
| 7700116 | Method of inducing an immune response in a host by administering immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane A method of developing an immune response to HIV using a composition of inactivated HIV. Inactivation is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune re... | 04/20/2010 |
| 7700115 | Therapeutic peptides and vaccines Compositions are disclosed that induce broadly HIV therapeutic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the ide... | 04/20/2010 |
| 7658932 | Method of making immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane A method of making an immunogenic composition using inactivated HIV. Inactivation of HIV is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In pa... | 02/09/2010 |
| 7618642 | Expression cassettes encoding modified human immunodeficiency virus type 1 subtype C envelope glycoproteins The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described. ... | 11/17/2009 |
| 7608273 | Recombinant lentivirus encoding modified GP 120 signal sequences Novel HIV vaccines comprising an avirulent and non-cytolytic recombinant HIVs are provided. ... | 10/27/2009 |
| 7592014 | Stabilized viral envelope proteins and uses thereof This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains o... | 09/22/2009 |
| 7556814 | Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane An antigenic and immunogenic composition of predetermined inactivated strains of human immunodeficiency virus (HIV) is disclosed. Inactivation is through psoralen and ultraviolet radiation; the composition is rendered more effective by the removal of structural feat... | 07/07/2009 |
| 7534442 | Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid The present invention is directed to immunogenic conjugates comprised of a polymer, preferably a polysaccharide, with a covalently attached antigen and an agent for boosting a patient's immune response. The conjugates may be used in vaccines for a wide range of dise... | 05/19/2009 |
| 7531181 | Gp120 specific antigens and uses thereof The present invention provides multi-antigenic constructs comprising one or more carbohydrate antigens having the formula: wherein R1, R2A, R2B | 05/12/2009 |
| 7517532 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors 8,9-Dihydroxydihydropyridopyrazine-1,6-diones and 8,9-dihydroxypyridopyrazine-1,6-diones are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the pyridopyrazinediones are of Formula (I): (I), wherein R1, R2, R | 04/14/2009 |
| 7507417 | Immunogenic compositions comprising human immunodeficiency virus type 2 (HIV-2) glycosylated and unglycosylated envelope proteins and their methods of preparation Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, res... | 03/24/2009 |
| 7491400 | Pharmaceutical compositions comprising attenuated HIV-1 nef-deficient viral particles A therapeutic suspension for the treatment of human immunodeficiency virus type I (HIV-1) infection in humans using isolated and purified HIV-1 nef-deficient viral particles having a nef-deletion between the endonuclease cleavage sites Nco I and Xho I. ... | 02/17/2009 |
| 7488485 | DNA vaccine compositions and methods of use The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered saf... | 02/10/2009 |
| 7488484 | Nucleic acid expression cassette encoding an HIV polyprotein comprising the ancillary gene products Vif, Vpu, and Nef Improved vaccines and methods of using the same are disclosed. Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed. ... | 02/10/2009 |
| 7482016 | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides The present invention provides compositions, including immunogenic compositions, comprising acetylated Tat protein of an immunodeficiency virus. The present invention further provides antibodies that specifically bind an acetylated Tat polypeptide. The present inven... | 01/27/2009 |
| 7470430 | Modifications of HIV, ENV, GAG, and POL enhance immunogenicity for genetic immunization Modified HIV Env, Gag, Pol, or Nef DNA with improved ability to elicit antibody and CTL responses to HIV antigens have been identified as prototype immunogens for the treatment and prevention of HIV infections. Modifications to Env glycoprotein include deletions in ... | 12/30/2008 |
| 7442525 | Method for expressing HIV polypeptides Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare... | 10/28/2008 |
| 7439052 | Method of making modified immunodeficiency virus particles Described are a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. Solvents useful for extracting ... | 10/21/2008 |
| 7429653 | Stabilized soluble glycoprotein trimers The present application is directed to stabilized HIV envelope glycoprotein trimers. The trimers are stabilized by introducing trimeric motifs, preferably the GCN4 coiled coil or the fibritin trimeric domain, at certain sites, for example in the gp41 ectodomain. The... | 09/30/2008 |
| 7427468 | Anti-TSG101 antibodies and their uses for treatment of viral infections The present invention provides methods of using antibodies that bind a TSG101 protein to inhibit or reduce viral production. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV infection. The invent... | 09/23/2008 |
| 7407663 | Modified immunodeficiency virus particles The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solv... | 08/05/2008 |
| 7407662 | Modified viral particles with immunogenic properties and reduced lipid content The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employ... | 08/05/2008 |
| 7399473 | Virus coat protein/receptor chimeras and method of use The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties charac... | 07/15/2008 |
| 7393630 | Use of microparticles combined with submicron oil-in-water emulsions Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submi... | 07/01/2008 |
| 7390624 | Metal chelate-labelled peptides The invention concerns a process for the production of metal chelate-labelled peptide antigens, peptides obtainable by this process and their use in an immunological method of detection. ... | 06/24/2008 |
| 7384637 | Drug for AIDS treatment Raising the T-cell count in an HIV positive patient having a low T-cell count by orally administering an effective amount of a composition containing a material obtained by treating whole human blood or white cells obtained from HIV positive patients with cold aqueo... | 06/10/2008 |
| 7384641 | Immuno-modulating effects of chemokines in DNA vaccination The present invention relates to a composition and method for enhancing the efficacy of a vaccine in a subject treated with the vaccine by administering to the subject an antigen in conjunction with a chemokine. ... | 06/10/2008 |
| 7378515 | Synthetic gagpol genes and their uses The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and v... | 05/27/2008 |
